Due to a weak relationship with patients characteristics it is difficult to indicate any clinical usefulness of testing NR3C1 or NR3C2 expression but our data support the clinically relevant roles of the receptors expression levels in functioning corticotroph pituitary tumors. Here, NR3C2 is linked to pituitary tumor.